New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
07:11 EDTGSK, RGDXResponse Genetics receives third GSK milestone payment
Response Genetics (RGDX) announced that it has achieved its third milestone payment from GlaxoSmithKline (GSK) related to the issuance of a U.S. patent for detection of BRAF Mutations.In support of the development of Tafinlar, in March 2010, GSK entered into a non-exclusive license agreement with Response Genetics whereby Response Genetics granted GSK a non-exclusive, sublicenseable license to its proprietary PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples. The agreement entitled Response Genetics to certain milestone payments. Response Genetics earned its first milestone payment of $500,000 in July of 2012 for submission of the first Premarket Approval and its second milestone payment of $500,000 in May 2013 for the FDA's approval of the PMA. Response Genetics has now earned its third milestone payment of $500,000 upon notice that its patent entitled "Methods, Primers, Probes and Kits Useful for the Detection of BRAF Mutations" was allowed by the United States Patent and Trademark Office.
News For RGDX;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
09:21 EDTGSKOn The Fly: Pre-market Movers
Subscribe for More Information
07:15 EDTGSKAgenus reports GSK ZOE-50 Phase 3 study met primary endpoint
Subscribe for More Information
December 11, 2014
07:09 EDTRGDXResponse Genetics secures NYS Department of Health approval for ResponseDX
Subscribe for More Information
December 10, 2014
15:03 EDTRGDXResponse Genetics rises 18% to 54c
Subscribe for More Information
December 9, 2014
10:23 EDTGSKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:10 EDTGSKARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
07:44 EDTGSKAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:37 EDTGSKGlaxoSmithKline downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill downgraded GlaxoSmithKline to Underperform citing a lack of pipeline catalysts and its belief the European pharma sector is close to fair value.
December 8, 2014
13:32 EDTGSKEpizyme announces results for PRMT5 inhibitor
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use